Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by HuntNGatheron Sep 20, 2010 12:40pm
527 Views
Post# 17469251

Strong Inertia Needs to be Overcome

Strong Inertia Needs to be OvercomeAnother day, another flat line on SSS.

I am a little bit surprised that we saw pretty much zero after the last NR came out.
That NR, released on May 25 would have been enough to take the SP to 60 or at least hold the position with full faith that we would be  heading into Ph3.

Because we tripped on the placebo measure, we lost all that momentum and positive feeling around the stock.

I am not here to pump the stock.  I am here to try and get a grip  on what it will take to push this thing back into motion again.

Since May 25th we have had
a) cost cutting measures to keep spending down and allow for more time to get other things moving
b) approval for an open label TBI study
c) major insider action with new blood taking big positions in the stock.
d) follow-up results showing that the results released on May 25th failed to tell the story because they were the wrong endpoints and the timeline was not long enough to appreciate the changes.

For that (d) we move up an eyelash, and nothing more.

It seems to me that Phase 3 is a likely conclusion.  We will get a partner and move forward when the FDA is done considering their decision.  If the regimen makes sense and works (when measured appropriately) then why wouldn't someone ante up.  We are pretty damn cheap right now.

Was there really such limited shareholder depth here that the same 100 people are staring at each other from across the room to see who will make the first move?

What will it take.

I would love to hear some real thoughts on the matter.

Of course, do your own DD at all times.
Bullboard Posts